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ABSTRACT
Introduction: Gastric cancer represents a great
challenge for healthcare providers and requires a
multidisciplinary treatment approach in which surgery
plays a major role. Minimally invasive surgery has
been progressively developed, first with the advent of
laparoscopy and recently with the spread of robotic
surgery, but a number of issues are currently being
debated, including the limitations in performing an
effective extended lymph node dissection, the real
advantages of robotic systems, the role of
laparoscopy for Advanced Gastric Cancer, the
reproducibility of a total intracorporeal technique and
the oncological results achievable during long-term
follow-up.
Methods and analysis: A multi-institutional
international database will be established to evaluate
the role of robotic, laparoscopic and open approaches
in gastric cancer, comprising of information regarding
surgical, clinical and oncological features. A chart
review will be conducted to enter data of participants
with gastric cancer, previously treated at the
participating institutions. The database is the first of
its kind, through an international electronic
submission system and a HIPPA protected real time
data repository from high volume gastric cancer
centres.
Ethics and dissemination: This study is conducted
in compliance with ethical principles originating from
the Helsinki Declaration, within the guidelines of
Good Clinical Practice and relevant laws/regulations.
A multicentre study with a large number of patients
will permit further investigation of the safety and
efficacy as well as the long-term outcomes of robotic,
laparoscopic and open approaches for the
management of gastric cancer.
Trial registration number: NCT02325453; Pre-results.
INTRODUCTION
Background
Gastric cancer constitutes a major health
problem and is rampant in many parts of the
Strengths and limitations of this study
▪ The scientific literature highlights that large
samples of patients are needed to evaluate the
safety and verify the potential advantages of min-
imally invasive surgery for gastric cancer.
▪ This project will create the most extensive multi-
centre database of patients receiving subtotal or
total gastrectomy with the robotic, laparoscopic
or open approach, involving institutions with
experience in gastric and minimally invasive
surgery.
▪ A software system of online submission and
sharing of patient data through a dedicated and
protected website has been adopted for this
study.
▪ Analysis of data must consider differences
regarding the surgical techniques and patient
management.
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world. By some estimates, it is the fourth most common
cancer.1 In certain Eastern Asian countries where
screening is widely performed, early detection is often
possible. In other parts of the world, it continues to pose
a major challenge for healthcare professionals.
Surgery is the primary treatment for patients with
resectable disease. Subtotal gastrectomy is the preferred
approach for distal gastric cancers. Whereas, proximal
gastrectomy and total gastrectomy are indicated for
proximal gastric cancers.2
Resection should include lymph node dissection;
however, the extent of lymphadenectomy remains con-
troversial. Gastrectomy with D2 lymph node dissection is
the standard treatment for curable gastric cancer in
Eastern Asia. In the West, D2 dissection is considered to
be a recommended but not compulsory procedure.
However, there is uniform consensus that the removal of
an adequate number of nodes, 15 or greater, is benefi-
cial for staging purposes.
Minimally invasive surgery (MIS) is progressively emer-
ging in the management of gastric cancer through the
development of new surgical devices and the advance-
ment of surgical techniques.
Starting with Kitano et al,3 who performed the first
laparoscopy-assisted distal gastrectomy in 1994, the use of
laparoscopy has continued to grow and, recently,
robotic-assisted gastrectomy was reported in 2003 by
Hashizume and Sugimachi.4 Robotic gastrectomy has
rapidly spread because of its potential technical advan-
tages, such as the precision of movements achieved using
articulated instruments and a three-dimensional view.
MIS is generally accepted as an alternative to open
surgery in the treatment of Early Gastric Cancer,5
whereas for Advanced Gastric Cancer, the reliability of
laparoscopy depends largely on the proper execution of
D2 lymph-node dissection.6 7
To date, many technical aspects of the surgical treat-
ment are still controversial and lack solid evidence
regarding both short-term clinical and long-term onco-
logical outcomes.8
In particular, it is debated whether complete and safe
lymph-node dissection is possible with MIS.
Robotic technology could overcome the difficulties of
traditional laparoscopy, but the theoretical advantages in
lymph-node dissection have not yet been proven and
verified.
Recently performed meta-analyses have been poor
due to the small number of studies of good quality.9–13
There are several limitations highlighted in the
current literature including the different baseline
characteristics of patients, the relatively small sample
sizes, the high heterogeneity of data, the lack of basic
features regarding the procedures, such as the type of
surgical reconstruction, and the inadequate or non-
accessibility of data regarding both the short-term
period and the oncological follow-up.
This project aimed to create the most extensive multi-
centre database, to date, of patients receiving gastric
surgery using a robotic, laparoscopic or open approach,
involving institutions with experience in gastric and
MIS.14
Rationale
The research areas in the context of MIS are particularly
directed towards evaluating the possible advantages of
laparoscopic versus open surgery in perioperative out-
comes and quality of life while respecting oncological
principles.
Although there is growing attention concerning the
role of MIS for gastric cancer, the current level of evi-
dence on this topic is very low. There have been only six
RCTs comparing laparoscopic versus open gastrec-
tomy15–20 and no RCTs have been performed for robotic
surgery.
In addition, the extreme heterogeneity of most studies
is based on the absence of evidence-based practice
guidelines.
Laparoscopic gastric surgery (LGS) is regarded as a
technically feasible procedure as described in many
reports that have demonstrated its safety, in particular
for early gastric cancer (EGC); however, several studies
have reported differences linked to the surgeon’s experi-
ence and skill with laparoscopy, the hospital’s volume
and the surgeon’s volume of gastrectomy procedures,
and the accuracy of the preoperative diagnosis.
Over the past decade, robotic technology has provided
new tools for MIS.
The potential underlined advantages of the use of the
robotic system are essentially the following. The first
advantage is the possibility of performing an extended
lymphadenectomy to the level of the most complex
lymph node stations, and the other advantage is facilita-
tion of the performance of an intracorporeal anasto-
mosis. Current studies in the literature are inconsistent
for both these aspects.
The main problems found in clinical studies on
robotic and/or laparoscopic versus open surgery for
gastric cancer that should be overcome by a new study
are as follows:
▸ In some comparative studies, there is selection bias in
generating the comparative groups, in particular with
regard to differences in the stage of the disease; dif-
ferences that also could have been subjected to differ-
ent extensive surgeries.
▸ Most studies do not clearly indicate the specific
method of anastomotic technique such as intracorpor-
eal versus extracorporeal reconstruction. In centres
that perform intracorporeal anastomosis, the data are
often mixed with those of extracorporeal anastomosis.
▸ Some analyses of complications revealed that the
anastomotic leak rate was twice as high after laparo-
scopic and robotic procedures than after an open
approach, but there is a lack of information on the
method of reconstruction.
▸ Almost all of the studies comparing laparoscopic and
robotic surgery reported leaks. However, the same
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authors, in most cases, reported that the reconstruct-
ive phase of a robotic-assisted procedure was per-
formed in a laparoscopic or open manner. In such a
case, it is difficult to compare outcomes between the
two techniques.
▸ There are significant discrepancies between studies
concerning the length of hospital stay and post-
operative management of patients.
▸ In some centres, the decision to receive laparoscopic
versus robotic treatment is made by the patient after
informed discussion about the two minimally invasive
approaches, as the patient often incurs the extra
expense for robotic surgery.
Moreover, all of the studies that reported results in
this field emphasise the need for large randomised
trials. However, RCTs are difficult to perform and are
very costly. In fact, in many countries, and especially
those of East Asia, which also have significantly higher
numbers of patients with gastric cancer than others,
the patients themselves decide whether to undergo
robotic surgery because they have to pay for the
procedure.
There should be further consideration regarding the
need for the detection of numerous surgical, clinical
and oncological variables. Thus, it is imperative for such
a study to have a large number of patients enrolled.
Therefore, a multicentre study is desirable.
At present, a multicentre registry may represent the
best research method to assess the role of minimally
invasive approaches in gastric cancer by comparing the
methods to traditional open surgery.21
Therefore, for this project, a large registry will be
created by collecting data from the different participat-
ing centres to create a working basis for analysing out-
comes of interest and obtaining directions for further
investigation.
METHODS AND ANALYSIS
General study design
The overall purpose of this study is to develop and main-
tain an ongoing comprehensive multi-institutional data-
base comprising of information regarding surgical,
clinical and oncological features of patients undergoing
surgery for gastric cancer with robotic, laparoscopic or
open approaches and subsequent follow-up at participat-
ing centres.
The main objectives are:
▸ To determine the surgical, clinical and oncological
outcomes, in the short and long term.
▸ To compare results according to the type of interven-
tion, device used and manner of execution of differ-
ent surgical phases.
▸ To relate results of different surgeries with baseline
characteristics of patients and stage of disease.
The registry will allow centres to retrospectively enter
data of participants with gastric cancer treated at each
participating centre. Information gathered will be
obtained from existing records, diagnostic tests and sur-
gical intervention descriptions.
Information will be collected and recorded by all insti-
tutions through a specific online shared system (https://
imigastric.logix-software.it/).
To facilitate and standardise data collection, speed up
the creation of a shared database and ensure the secur-
ity of sensitive data, a special online computerised web
system has been developed.
The creation of a multi-institutional registry involves
many obstacles. So, the following critical issues were
considered.
As the investigators belong to centres located in differ-
ent parts of the world, there is a high risk of generating
transmission errors during the different stages of collec-
tion and submission of data.
In addition, individual investigators may have difficul-
ties in managing entered cases during different study
steps, which could induce them to leave the study.
For these reasons, the intent was to make the entering
and the sharing of data as easy as possible to increase
the chances of success of the registry in the retrospective
sense and to facilitate the possible plan for a prospective
phase in a future study.
Therefore, a system of online submission and sharing
of patient data through a dedicated and protected
website was planned.
The organising committee of the registry with the
cooperation of specialists in software programming,
created a website that is accessible only to investigators
using a password and username to log in, which are pro-
vided after the accreditation of each participating
centre.
Data are not sent via email or spreadsheets but
entered by each investigator directly through the web
portal.
Once logged into the portal, the investigator is able to
open a page where he or she can enter the required
data of the patient by simply filling out a form and
selecting the various features from dropdown lists made
available for each parameter.
In fact, to facilitate the submission of information and
its subsequent analysis, all of the features that have to be
entered have been previously standardised, so data are
selectable from the choices already made available,
without the need to write or specify anything else.
Investigators have to provide the required data as com-
pletely as possible; however, the absence of certain infor-
mation does not preclude sending the remaining data.
In fact, if some parameters are not recorded in patient
files or are not provided because of an institute’s policy,
the investigator can send only the data of the variables
at his disposal.
The web portal was designed in such a way that each
investigator has a personal protected page that is not
accessible by other participants. So investigators can
display real time entered patient data and manage their
information. However, at the same time, the protection
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of data of each patient is guaranteed, and the data are
editable only by the submitter.
In particular, the patient’s sensitive information is only
recognised by the investigator of the centre to which the
specific subject belongs. Moreover, the system provides
the use of a reference code for each patient, which
appears in the general shared registry instead of the
name.
In this manner, it is hypothesised that the maximum
chance for accuracy in the collection of data can be
achieved.
After the initial retrospective review, it will be possible
to proceed, with the agreement of the other investiga-
tors, to a prospective phase and the maintenance of the
database.
Specific aims
AIM 1: To compare robotic and laparoscopic surgery to
the open approach, in terms of safety and feasibility,
based on the intraoperative and postoperative outcomes.
AIM 2: To verify the respecting of oncological princi-
ples through minimally invasive approaches in relation
to the stage and location of the tumour by comparing
results to open surgery.
AIM 3: To verify whether minimally invasive approaches
ensure the same effectiveness as open surgery in terms of
overall survival and disease-free survival.
AIM 4: To compare the three treatment arms regard-
ing recovery of gastrointestinal function considering the
outcomes measured during the postoperative hospital
stay.
AIM 5: To compare the incidence, types and severity
of early postoperative complications after gastrectomy by
the three approaches according to the Clavien-Dindo
classification system.22
AIM 6: To compare the intracorporeal to the extracor-
poreal anastomosis to evaluate postoperative recovery
and complications.
AIM 7: To verify whether robotic gastrectomy, com-
pared to laparoscopic or open techniques, is capable of
reducing postoperative surgical stress.
Eligibility
Each patient is required to meet all of the inclusion cri-
teria and none of the exclusion criteria.
Inclusion criteria
▸ Histologically proven gastric cancer
▸ Preoperative staging work up performed by upper
endoscopy and/or endoscopic ultrasound, and CT
scan
▸ Early Gastric Cancer23 24
▸ Advanced Gastric Cancer23 24
▸ Patients treated with curative intent in accordance to
international guidelines2 25 26
Exclusion criteria
▸ Distant metastases: peritoneal carcinomatosis, liver
metastases, distant lymph node metastases,
Krukenberg tumours, involvement of other organs
▸ Patients with high operative risk as defined by the
American Society of Anesthesiologists (ASA) score >4
▸ History of previous abdominal surgery for gastric
cancer
▸ Synchronous malignancy in other organs
▸ Palliative surgery.
Data collection
Patient demographics
▸ Year of birth
▸ Sex
▸ Body mass index
▸ Surgical risk (ASA score)
▸ Concomitant illness
▸ Previous surgery
▸ Staging laparoscopy
▸ Peritoneal lavage cytology
▸ Neoadjuvant chemotherapy
▸ Neoadjuvant radiotherapy
▸ Preoperative blood samples: haemoglobin levels,
white blood cell count, granulocyte:lymphocyte (G:L)
ratio, plasma levels of total bilirubin
Surgery
▸ Operation date
▸ Type of surgical approach (open, laparoscopic,
robotic)
▸ Type of gastric resection (total gastrectomy, distal gas-
trectomy, pylorus-preserving gastrectomy, proximal
gastrectomy)2
▸ Type of reconstruction
▸ Anastomosis approach (intracorporeal,
extracorporeal)
▸ Anastomosis performance (linear stapler, circular
stapler, hand-sewn, robot-sewn)
▸ Site of minilaparotomy
▸ Length of minilaparotomy
▸ Placement of intra-abdominal drain
▸ Placement of nasogastric tube
▸ Total operative time
▸ Robot docking time
▸ Estimated blood loss
▸ Intraoperative blood transfusion
▸ Conversion to open surgery
▸ Intraoperative complications
▸ Intraoperative death
▸ Extent of lymphadenectomy2
▸ Proximal resection margin
▸ Distal resection margin
▸ Surgical margin status (R)
▸ Number of retrieved lymph nodes
Tumour
▸ Tumour location
▸ Long diameter of the tumour
▸ Depth of invasion (T classification)
▸ Number of metastatic lymph nodes
▸ Lymph node status (N classification)
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▸ AJCC pathological stage27
▸ Histological type28
▸ Lauren classification29
Postoperative clinical findings
▸ Enhanced recovery after surgery (ERAS) protocols
adopted
▸ Length of postoperative hospital stays
▸ Postoperative blood transfusion
▸ Patient mobilisation (post-operative day (POD) number)
▸ Liquid diet (POD number)
▸ Soft solid diet (POD number)
▸ Resumption of peristalsis (POD number)
▸ First flatus (POD number)
▸ Drain removal (POD number)
▸ Length of intravenous antibiotic use
▸ Length of intravenous analgesic use
Postoperative daily clinical findings (POD numbers 1, 3, 5, 7)
▸ Drain production
▸ Haemoglobin levels
▸ White cell count
▸ G:L ratio
▸ Plasma levels of total bilirubin
In-hospital postoperative complications
▸ Type of complication
▸ Reoperation for complication
▸ Clavien-Dindo grade22
Early and late surgery-related complications after discharge
▸ Date of occurrence
▸ Type of complication
▸ Death related to the complication
▸ Need of surgery
Follow-up
▸ Adjuvant chemotherapy
▸ Adjuvant radiotherapy
▸ Date of last follow-up visit
▸ Patient status at last follow-up visit (alive, dead, lost to
follow-up assessment)
▸ Disease-free or not during follow-up
Primary outcome measures
▸ Safety and feasibility of minimally invasive procedures:
rate of conversion to open surgery, rate of intraoperative
blood transfusion and average of estimated blood loss.
▸ Respect of oncological principles: number of lymph
nodes retrieved and rate of patients achieving R0
resection, at the histopathological analysis of the sur-
gical specimen.
▸ Effectiveness of surgery: overall survival and disease-
free survival achieved at 1 and 3 years from surgery.
This outcome will be evaluated at 5 years, depending
on the power of the statistical sample obtained at the
end of data collection.
Secondary outcome measures
▸ Recovery of gastrointestinal functions and physical
status allowing the discharge of the patient: time to
peristalsis, time to first flatus, time to start oral intake
and days of hospitalisation after surgery until
discharge.
▸ Early postoperative complications: rate of total com-
plications, rate of specific surgical complications,
severity of complications scored on the
Clavien-Dindo classification system,22 assessed during
hospitalisation.
▸ Safety and efficacy of intracorporeal anastomosis: rate
of anastomotic leakage, days of hospitalisation after
surgery until discharge.
▸ Postoperative surgical stress: G:L ratio30 recorded and
compared before and after surgery.
DEFINITIONS AND CLASSIFICATION ADOPTED
Intraoperative complications
These include any adverse event in the course of the
surgical procedure that resulted in additional surgical
manoeuvres with respect to the planned surgery, emer-
ging from the review of the written surgical report or
the anaesthesia chart, or data collected in institutional
databases.
Particularly, the rate of the following events will be
detected and analysed:
Bleeding: Any occurrence of relevant blood loss that
caused an action by the surgeon or anaesthesiologist,
directly described in the surgical and anaesthesiological
reports, or evidence in the anaesthesiological reports of
undertaken urgent transfusion therapy during surgery;
or intraoperative blood samples demonstrating an acute
loss of haemoglobin >1 g/L in the absence of significant
haemodilution; intraoperative bleeding reported in insti-
tutional databases.
Injury of visceral organs: Any injury to abdominal organs
described on the surgical report, requiring additional
surgical procedures; data derived from the analysis of
institutional databases.
Vascular lesions: Injury occurring to a major vessel
needing additional surgical actions, described by the
surgeon in the surgical report or reported in institu-
tional databases.
Mechanical trouble: Issues related to the failure of mech-
anical staplers described in the surgical report or
reported in institutional databases.
Anaesthesia complications: Any complications occurring
during surgery that induced the interruption of the
surgery or changed the normal course of the procedure,
described in the surgical or anaesthesiological report or
highlighted in institutional databases.
Other complications: Other events leading to a deviation
from the normal intraoperative course of the surgery,
reported by the surgeon or the anaesthetist or in
existing institutional databases.
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Postoperative complications
In-hospital postoperative complications: Any adverse event
leading to a deviation from the normal postoperative
course during a patient’s hospitalisation after surgery
until discharge.
The investigator can choose between three answers:
No, Yes, No data.
If a complication is detected, the investigator can
specify the type of complication by selecting it from a
predefined list, the need for surgery and the grade of
complication by the Clavien-Dindo scale.22
Early and late complications after discharge: Any adverse
surgery-related event after the patient’s discharge.
The following postoperative events will be detected
and analysed.
Bleeding: Any evidence of postoperative bleeding, col-
lected in institutional databases or described in any
medical reports, such as the following:
▸ Patient’s chart, description of clinical signs and symp-
toms, or the need for transfusion;
▸ Blood samples revealing an acute anaemia, assessed
by a decrease in serum haemoglobin;
▸ Report of radiological or endoscopic examinations;
▸ Report of surgical procedures.
The investigators can differentiate between intralum-
inal and intra-abdominal bleeding.
The former would be proven by endoscopic proce-
dures in patients with clinical signs and symptoms of
upper-gastrointestinal bleeding, such as haematemesis
or melena.
The latter if it is documented that a blood-stained
fluid in the intra-abdominal drains was reported in the
medical records, a bleeding testified by a radiology or
angiographic report or haemoperitoneum found on
re-laparotomy.
Anastomotic leakage: Any evidence of defect of the
gastrointestinal wall at the anastomotic sites leading to
a communication between the intraluminal and extra-
luminal compartments and involving the following:
gastroduodenostomy, gastrojejunostomy, oesophagojeju-
nostomy, jejunojejunostomy, duodenal stump. To detect
this complication, the following evidence will be consid-
ered: the proof of contrast material extravasation
during radiological examinations, defects reported in
endoscopic examinations, clinical records of persistent
bilious fluid in the abdominal drain, and the identifica-
tion of intestinal spillage during exploratory laparos-
copy or laparotomy along with data from institutional
databases.
Anastomotic stenosis: Any restriction at the anastomotic
site determining clinical symptoms reported in the
medical chart, and evidenced by radiological and endo-
scopic examinations along with data from institutional
databases.
Wound infection: Superficial and deep surgical-site
infections are both considered, from either those
reported in medical records or those coming from data
collected in institutional databases.
Superficial incisional infections are considered when
skin or subcutaneous tissue is involved, whereas deep
incisional infection is considered when extending into
the fascial layer.
Fluid collection/intra-abdominal abscess: Evidence of col-
lection of fluid material, with or without the character-
istics of an abscess, confirmed by contrast-enhanced CT
or coming from data collected in institutional databases.
Intestinal obstruction and ileus: Reported diagnosis based
on clinical examination and signs of intestinal dilatation
on abdominal X-ray/CT scan or when an anastomotic
stricture was confirmed by endoscopy; data reported in
institutional databases.
Incisional hernia: Hernia that occurred through a previ-
ously made surgical incision in the abdominal wall deriv-
ing either from laparotomy or trocar incisions.
All available data will be considered from medical
records, surgical monitoring visits, follow-up, reports of
surgeries and data collected from existing institutional
databases.
Other complications: Complications include surgical-
related complications, not classified by any of the above,
and deriving from all available patient records or institu-
tional databases.
Oncological follow-up
Evaluation of any reported action made after surgery to
monitor the disease and assess the status of the patient.
This is evaluated from an analysis of the patient’s onco-
logical chart, radiological examinations and institutional
databases.
The analysis will be made based on the following
parameters:
Last follow-up visit: Date of the last record reporting
the patient’s condition or the annotated date of death,
or date of the last reported contact between the patient
and the health centre.
Patient status: The patient’s condition (alive/dead) at
last follow-up check.
Lost to follow-up assessment: A patient who at one point,
after surgery, has become lost or unreachable, or has
moved away from the site.
Disease-free: The length of time after surgery that the
patient survives without any signs or symptoms of cancer.
This will be calculated according to the date of surgery
and the date of the first report (radiological controls),
attesting the recurrence of the disease until the last
follow-up visit if the patient has been disease free.
All radiological records will be considered using insti-
tutional radiological software or databases and the
patient’s oncological medical chart.
Other definitions
Operative time: The time between laparotomy and skin
suture for open gastrectomy (OG) and pneumoperito-
neum induction and port-site closure for laparoscopic
gastrectomy (LG) or robotic gastrectomy (RG)
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(including, in this case, the time necessary to dock the
robotic cart). Evaluated from the analysis of the surgical
report.
Blood loss: Suction volume minus irrigation volume.
Evaluated from the analysis of the surgical and anaesthe-
siological reports.
Need for blood transfusion: Proof of the performed trans-
fusion attached in the medical record, either in the
operative or postoperative period.
Type of procedure: Gastrectomy and extent of lymphade-
nectomy will be classified in accordance with the
Japanese Gastric Cancer Association ( JGCA)
guidelines.2
Staging tumour: The stage will be described according
to the Seventh Edition of the American Joint Committee
on Cancer American Joint Committee/International
Union against Cancer tumour node metastasis classifica-
tion for gastric cancer.27 31
Curative resection: This will be defined as an R0 resec-
tion using the AJCC residual tumour classification in
accordance with the JGCA guidelines.2
Postoperative stress: As a surgical stress marker, the G:L
ratio will be analysed comparing preoperatively and post-
operative values, deriving from performed blood
analysis.30
Statistical analysis
Based on the data of the registry, every investigator can
perform all the statistical analysis he or she needs for
research purposes, while a basic analysis for monitoring
the study will be performed as follows. SPSS V.22 will be
used to carry out this statistical analysis. The dichotom-
ous variables will be expressed as numbers and percen-
tages, while continuous variables will be expressed as
mean and SD, or median and IQR (minimum and
maximum values). Continuous variables will be com-
pared using one-way analysis of variance with post hoc
multiple comparison by Tukey’s procedure. Pearson’s χ2
test or Fisher’s exact test, as appropriate, will be used for
analysis of categorical data. For each of these tests a
value of α<0.05 will be considered statistically significant.
Sample size
It is estimated from recent meta-analyses12 that the rate
of procedures performed with MIS at referral institutes
for gastric cancer, considering patients who follow inclu-
sion and exclusion criteria of this protocol, is 35%.
According to the number and volume of the partici-
pating centres and to reach a sample of 2800 partici-
pants treated with laparoscopic or robotic surgery, is
estimated that data of at least 8000 patients need to be
collected.
Study period and sites
The study (NCT02325453) takes into account data of
patients treated from 1 January 2000, to the official
opening of the registry (14 May 2015).
The maintenance of the registry is currently guaran-
teed until 1 January 2018. At the end of this period the
system could continue to be active and in any case, even
after this period, the collected data will be made safe
and available to all involved centres.
This study is shared by the members of the inter-
national study group on MIS for gastric cancer
(IMIGASTRIC).14 The group involves some of the most
important researchers and institutes for the treatment of
gastric cancer around the world, and began working in
2014 to reach a definitive agreement on the principles,
objectives, data to be collected and software tools of the
study.
During the study period, other interested institutions
can join the registry, thus increasing the size of the
samples and allowing new statistical analysis.
Also, the opening of a prospective trial will be possible
after sharing specific protocol.
ETHICS AND DISSEMINATION
Ethical aspects
All the investigators agree to conduct the study in com-
pliance with ethical principles originating from the
Helsinki Declaration, within the guidelines of Good
Clinical Practice and applicable laws.
The investigators shall undertake to act according to
the rules of the Institutional Review Board (IRB) and
Ethics Committee (EC) regarding the retrospective col-
lection of data.
Potential risks and safety management
Participation in the research registry involves the poten-
tial risks of a breach of confidentiality of the medical
record information and associated privacy of
participants.
Such risks will be minimised by the use and establish-
ment of appropriate tailor-made systems, as specified in
the sections above, developed by experts in web security.
In particular, confidentiality and data security will be
ensured by:
1. Removing direct participant identifiers (ie, names,
social security numbers and medical record
numbers) from the information stored in the
research registry;
2. Securing in a separate location and limiting access to
information linking codes assigned to the registry
information with direct participant identifiers;
3. Limiting access to information contained within the
research registry to centre investigators.
The data and safety monitoring plan for the research
registry will involve routine (ie, quarterly) monitoring by
the organising committee of (1) the removal of direct
identifiers from information contained with the research
registry, (2) the documentation of investigator access to
the research registry, (3) the security of the database
linking the research registry linkage codes with partici-
pant identifiers and the documentation of investigator
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access to this database and (4) any conditions that may
negatively impact the confidentiality of information con-
tained within the research registry.
In addition, any unauthorised access to medical
record information contained within the research regis-
try or to the database linking the registry information to
participant direct identifiers shall be reported to a data
and safety monitoring board.
The organising committee will ensure that confiden-
tial information will be secured and that Protected
Health Information (PHI) will not be revealed. Access
to subject information will be limited to the study per-
sonnel and PHI will be kept in a separate secure storage.
Study’s website
A study website is available at: http://www.imigastric.
com to follow news and daily updates of the project and
to interact with the investigators.
Contact information for the organising secretariat and
the coordinating staff is available there.
Publications
Each participating centre, with equal right, will be able
to access the data of the registry, perform statistical ana-
lysis, discuss the results and freely write scientific manu-
scripts. However, each study that is generated based on
the registry must be disseminated to all the centres
before final publication.
Author affiliations
1Department of Digestive Surgery, St Mary’s Hospital, University of Perugia,
Terni, Italy
2Department of General Surgery, Jinling Hospital, Medical School, Nanjing
University, Nanjing, China
3Department of Surgery, Division of Gastrointestinal Surgery, University of
California, Irvine Medical Center, Orange, California, USA
4Chirurgische Klinik und Poliklinik, Klinikum Rechts der Isar der Technischen
Universität München, München, Germany
5Department of General Surgery, School of Medicine, Istanbul Medeniyet
University, Istanbul, Turkey
6Unité des Maladies de l’Appareil Digestif et Endocrine (UMADE), Centre
Hospitalier de Luxembourg, Luxembourg, Luxembourg
7Department of General Surgery, Third Military Medical University Southwest
Hospital, Chongqing, China
8Division of General Surgery, Sunnybrook Health Sciences Centre, Toronto,
Canada
9Department of Gastrointestinal Surgery, Tianjin Medical University General
Hospital, Tianjin, China
10Division of General Surgery, Medstar Georgetown University Hospital,
Washington DC, USA
11Department of Surgery, Ruijin Hospital, Shanghai Jiaotong University,
School of Medicine, Shanghai, China
12Department of Surgical Oncology and HPB Surgery, Englewood Hospital
and Medical Center, Englewood, New Jersey, USA
13Department of Gastroenterological Surgery, Osaka University Graduate
School of Medicine, Osaka, Japan
14Service de chirurgie digestive et cancérologique CHU Bocage. Dijon, France
15Department of Surgery, National Defense Medical College, Tokorozawa,
Japan
16Division of Oncological and Robotic Surgery, Department of Oncology,
Careggi University Hospital, Florence, Italy
17Department of General Surgery, Division of General, Gastroenterologic and
Minimally Invasive Surgery, GB Morgagni Hospital, Forlì, Italy
18Digestive and Hepatobiliary Surgery Department, University of Auvergne,
University Hospital Estaing, Clermont-Ferrand, France
19Department of Surgery and Translational Medicine, Center of Oncological
Minimally Invasive Surgery (COMIS), University of Florence, Florence, Italy
Acknowledgements CARIT foundation (Fondazione Cassa di Risparmio di
Terni e Narni) for financial support. LOGIX Srl provided IT study solutions.
Contributors AP, JD were involved in conception of the study. AP, NTN, SZ,
Z-WJ, DR, STB, J-SA, OF, OA, PGJ, HT, YK, LZ, NGC, P-WY, BZ, FQ, MA, FB,
AA, JG, DP, AN, MG, J-BL, TE, ML, WA-R, ST, JM, Y-LZ, TL, AC, FC, BB, ST
and JD were involved in designing the study. MA, FB, AA, JG, DP, AN, MG,
J-BL, TE, ML, WA-R, ST, JM, Y-LZ, TL, AC, FC, BB, ST and JD were involved
in analysing the literature and references searching. AP, NTN, SZ, Z-WJ, DR,
STB, J-SA, OF, OA, PGJ, HT, YK, LZ, NGC, P-WY, BZ, FQ, ST and JD were
involved in drafting the rationale. AP, NTN, SZ, Z-WJ, DR, STB, J-SA, OF, OA,
PGJ, HT, YK, LZ, NGC, P-WY, BZ, FQ, ST and JD were involved in description
of the study methods and the study development. AP, NTN, SZ, Z-WJ, DR,
STB, J-SA, OF, OA, PGJ, HT, YK, LZ, NGC, P-WY, BZ, FQ, MA, FB, AA, JG,
DP, AN, MG, J-BL, TE, ML, WA-R, ST, JM, Y-LZ, TL, AC, ST and JD were
involved in evaluation and description of the study software system.
Funding The IMIGASTRIC project is supported by CARIT Foundation
(Fondazione Cassa di Risparmio di Terni e Narni), an organisation that
supports non-profit research for the St Mary’s Hospital of Terni and University
of Perugia (grant number: 0024137, approved 12/11/2014).
Competing interests None declared.
Ethics approval This study is conducted in compliance with ethical principles
originating from the Helsinki Declaration, within the guidelines of Good
Clinical Practice and relevant laws/regulations.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Kamangar F, Dores G, Anderson W. Patterns of cancer incidence,
mortality, and prevalence across five continents: defining priorities to
reduce cancer disparities in different geographic regions of the
world. J Clin Oncol 2006;24:2137–50.
2. Japanese Gastric Cancer Association. Japanese gastric
cancer treatment guidelines 2010 (ver. 3). Gastric Cancer
2011;14:113–23.
3. Kitano S, Iso Y, Moriyama M, et al. Laparoscopy-assisted Billroth I
gastrectomy. Surg Laparosc Endosc 1994;4:146–8.
4. Hashizume M, Sugimachi K. Robot-assisted gastric surgery. Surg
Clin North Am 2003;83:1429–44.
5. Montgomery M, Fukuhara S, Karpeh M, et al. Evidence-based
review of the management of early gastric cancer. Gastroenterol
Rep (Oxf) 2013;1:105–12.
6. Azagra JS, Ibanez-Aguirre JF, Goergen M, et al. Long-term results
of laparoscopic extended surgery in advanced gastric cancer:
a series of 101 patients. Hepatogastroenterology 2006;53:
304–8.
7. Vinuela EF, Gonen M, Brennan MF, et al. Laparoscopic versus open
distal gastrectomy for gastric cancer: a meta-analysis of randomized
controlled trials and high-quality nonrandomized studies. Ann Surg
2012;255:446–56.
8. Alimoglu O, Atak I, Eren T. Robot-assisted laparoscopic (RAL)
surgery for gastric cancer. Int J Med Robot 2014;10:257–62.
9. Shen WS, Xi HQ, Chen L, et al. A meta-analysis of robotic versus
laparoscopic gastrectomy for gastric cancer. Surg Endosc
2014;28:2795–802.
10. Marano A, Choi YY, Hyung WJ, et al. Robotic versus laparoscopic
versus open gastrectomy: a meta-analysis. J Gastric Cancer
2013;13:136–48.
11. Liao G, Chen J, Ren C, et al. Robotic versus open gastrectomy for
gastric cancer: a meta-analysis. PLoS ONE 2013;8:e81946.
8 Desiderio J, et al. BMJ Open 2015;5:e008198. doi:10.1136/bmjopen-2015-008198
Open Access
group.bmj.com on April 6, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
12. Hyun MH, Lee CH, Kim HJ, et al. Systematic review and
meta-analysis of robotic surgery compared with conventional
laparoscopic and open resections for gastric carcinoma. Br J Surg
2013;100:1566–78.
13. Xiong B, Ma L, Zhang C. Robotic versus laparoscopic gastrectomy
for gastric cancer: a meta-analysis of short outcomes. Surg Oncol
2012;21:274–80.
14. Parisi A, Desiderio J. Establishing a multi-institutional registry to
compare the outcomes of robotic, laparoscopic, and open surgery
for gastric cancer. Surgery 2015;157:830–1.
15. Hayashi H, Ochiai T, Shimada H, et al. Prospective randomized
study of open versus laparoscopy-assisted distal gastrectomy with
extraperigastric lymph node dissection for early gastric cancer. Surg
Endosc 2005;19:1172–6.
16. Huscher CG, Mingoli A, Sgarzini G, et al. Laparoscopic versus open
subtotal gastrectomy for distal gastric cancer: five-year results of a
randomized prospective trial. Ann Surg 2005;241:232–7.
17. Kim HH, Hyung WJ, Cho GS, et al. Morbidity and mortality of
laparoscopic gastrectomy versus open gastrectomy for gastric
cancer: an interim report—a phase III multicenter, prospective,
randomized Trial (KLASS Trial). Ann Surg 2010;251:417–20.
18. Kim YW, Baik YH, Yun YH, et al. Improved quality of life outcomes
after laparoscopy-assisted distal gastrectomy for early gastric
cancer: results of a prospective randomized clinical trial. Ann Surg
2008;248:721–7.
19. Kitano S, Shiraishi N, Fujii K, et al. A randomized controlled trial
comparing open vs laparoscopy-assisted distal gastrectomy for the
treatment of early gastric cancer: an interim report. Surgery
2002;131(1 Suppl):S306–11.
20. Lee JH, Han HS. A prospective randomized study comparing open
vs laparoscopy-assisted distal gastrectomy in early gastric cancer:
early results. Surg Endosc 2005;19:168–73.
21. Parisi A, Nguyen NT, Reim D, et al. Current Status of Minimally
Invasive Surgery for Gastric Cancer: a literature review to highlight
studies limits. Int J Surg 2015.
22. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo
classification of surgical complications: five-year experience. Ann
Surg 2009;250:187–96.
23. Japanese Gastric Cancer Association. Japanese classification of
gastric carcinoma: 3rd English edition. Gastric Cancer 2011;14:
101–12.
24. Murakami T. Pathomorphological diagnosis. Definition and gross
classification of early gastric cancer. Gann Monogr Cancer Res
1971;11:53–5.
25. NCCN. Clinical Practice Guidelines in Oncology: Gastric Cancer.
2014. http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
Version I.2014.
26. Waddell T, Verheij M, Allum W, et al. Gastric cancer:
ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis,
treatment and follow-up. Eur J Surg Oncol 2014;40:584–91.
27. Washington K. 7Th edition of the AJCC cancer staging manual:
stomach. Ann Surg Oncol 2010;17:3077–9.
28. Bosman F, Carneiro F, Hruban R, et al. WHO classification of
tumours of the digestive system. 4th edn. IARC, 2010.
29. Lauren P. The two histological main types of gastric carcinoma: diffuse
and so-called intestinal-type carcinoma. An attempt at a histo-clinical
classification. Acta Pathol Microbiol Scand 1965;64:31–49.
30. Tabuchi T, Shimazaki J, Satani T, et al. The perioperative
granulocyte/lymphocyte ratio is a clinically relevant marker of
surgical stress in patients with colorectal cancer. Cytokine
2011;53:243–8.
31. Edge SB, Compton CC. The American Joint Committee on Cancer:
the 7th edition of the AJCC cancer staging manual and the future of
TNM. Ann Surg Oncol 2010;17:1471–4.
Desiderio J, et al. BMJ Open 2015;5:e008198. doi:10.1136/bmjopen-2015-008198 9
Open Access
group.bmj.com on April 6, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
IMIGASTRIC−−Cancer
 Minimally Invasive surgery for GASTRIc
 protocol of the International study group on
 multi-institutional chart review. A study
 and oncological outcomes: a
 gastric cancer compared on surgical, clinical
 Robotic, laparoscopic and open surgery for
Takiguchi, Jean-Baptiste Lequeu, Stefano Trastulli and Amilcare Parisi
Yong-Liang Zhao, Tong Liu, Waddah Al-Refaie, Junjun Ma, Shuji 
Novotny, Tunc Eren, Metin Leblebici, Martine Goergen, Ben Zhang,
Gagniere, Denis Pezet, Fabio Cianchi, Benedetta Badii, Alexander 
Annecchiarico, Francesca Bazzocchi, Andrea Avanzolini, Johan
Kurokawa, Olivier Facy, Hironori Tsujimoto, Andrea Coratti, Mario 
Coburn, Feng Qi, Patrick G Jackson, Lu Zang, Steven T Brower, Yukinori
Reim, Orhan Alimoglu, Juan-Santiago Azagra, Pei-Wu Yu, Natalie G 
Jacopo Desiderio, Zhi-Wei Jiang, Ninh T Nguyen, Shu Zhang, Daniel
doi: 10.1136/bmjopen-2015-008198
2015 5: BMJ Open 
 http://bmjopen.bmj.com/content/5/10/e008198
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/5/10/e008198
This article cites 27 articles, 2 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (354)Surgery
 (392)Oncology
 (186)Gastroenterology and hepatology
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on April 6, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on April 6, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
